Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D M Miller

Showing results (271-280 of 305) with videos related to

Pageof 31
Sort By:
Transplantation|October 9, 1999
Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomideW J Waldman, D A Knight, N S Lurain, et al.
Stroke|November 1, 1982
Progress in cerebrovascular disease: local cerebral blood flow by xenon enhanced CTD Gur, S K Wolfson, H Yonas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 6, 2024
Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorderJ R Abbatemarco, A Aboseif, C Swetlik, et al.
The Journal of Burn Care & Rehabilitation|July 1, 1986
Burn depth evaluation with fluorometry: is it really definitive?K S Black, C W Hewitt, D M Miller, et al.
The American Journal of the Medical Sciences|July 1, 1990
Oncogenes, malignant transformation, and modern medicineD M Miller, S Blume, M Borst, et al.
Biotechniques|May 25, 1999
Two-color GFP expression system for C. elegansD M Miller, N S Desai, D C Hardin, et al.
Gene Therapy|April 1, 1996
Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexesS W Ebbinghaus, N Vigneswaran, C R Miller, et al.
The Journal of Experimental Medicine|March 28, 1998
Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathwayD M Miller, B M Rahill, J M Boss, et al.
Nature|February 27, 1992
C. elegans unc-4 gene encodes a homeodomain protein that determines the pattern of synaptic input to specific motor neuronsD M Miller, M M Shen, C E Shamu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 6, 2005
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patientsR A Rudick, G R Cutter, M Baier, et al.
Pageof 31

Showing results (271-280 of 305) with videos related to

Sort By:
Pageof 31
Transplantation|October 9, 1999
Novel mechanism of inhibition of cytomegalovirus by the experimental immunosuppressive agent leflunomideW J Waldman, D A Knight, N S Lurain, et al.
Stroke|November 1, 1982
Progress in cerebrovascular disease: local cerebral blood flow by xenon enhanced CTD Gur, S K Wolfson, H Yonas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 6, 2024
Neighborhood disadvantage, race, and clinical outcomes in neuromyelitis optica spectrum disorderJ R Abbatemarco, A Aboseif, C Swetlik, et al.
The Journal of Burn Care & Rehabilitation|July 1, 1986
Burn depth evaluation with fluorometry: is it really definitive?K S Black, C W Hewitt, D M Miller, et al.
The American Journal of the Medical Sciences|July 1, 1990
Oncogenes, malignant transformation, and modern medicineD M Miller, S Blume, M Borst, et al.
Biotechniques|May 25, 1999
Two-color GFP expression system for C. elegansD M Miller, N S Desai, D C Hardin, et al.
Gene Therapy|April 1, 1996
Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexesS W Ebbinghaus, N Vigneswaran, C R Miller, et al.
The Journal of Experimental Medicine|March 28, 1998
Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathwayD M Miller, B M Rahill, J M Boss, et al.
Nature|February 27, 1992
C. elegans unc-4 gene encodes a homeodomain protein that determines the pattern of synaptic input to specific motor neuronsD M Miller, M M Shen, C E Shamu, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 6, 2005
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patientsR A Rudick, G R Cutter, M Baier, et al.
Pageof 31